Daiwa Securities Group
BCYC

Daiwa Securities Group’s Bicycle Therapeutics BCYC Stock Holding History

Daiwa Securities Group’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-103
Closed -$1K – 1223
2025
Q4 		$1K Hold
103
– – ﹤0.01% 1342
2025
Q3 		$1K Hold
103
– – ﹤0.01% 1302
2025
Q2 		$1K Hold
103
– – ﹤0.01% 1251
2025
Q1 		$1K Hold
103
– – ﹤0.01% 1216
2024
Q4 		$1K Hold
103
– – ﹤0.01% 1248
2024
Q3 		$2K Hold
103
– – ﹤0.01% 1214
2024
Q2 		$2K Hold
103
– – ﹤0.01% 1243
2024
Q1 		$3K Hold
103
– – ﹤0.01% 1233
2023
Q4 		$2K Hold
103
– – ﹤0.01% 1264
2023
Q3 		$2K Hold
103
– – ﹤0.01% 1213
2023
Q2 		$3K Hold
103
– – ﹤0.01% 1215
2023
Q1 		$2K Hold
103
– – ﹤0.01% 1207
2022
Q4 		$3K Buy
103
+45
+78% +$1.21K ﹤0.01% 1188
2022
Q3 		$1K Hold
58
– – ﹤0.01% 1275
2022
Q2 		$1K Hold
58
– – ﹤0.01% 1277
2022
Q1 		$3K Hold
58
– – ﹤0.01% 1211
2021
Q4 		$4K Buy
+58
New +$3.2K ﹤0.01% 1215

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Daiwa Securities Group's BCYC Position: Q1 2026 in Review

Daiwa Securities Group sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 103 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in BCYC in Q4 2021 and held it in 17 quarters. The position peaked at $4K in Q4 2021. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Daiwa Securities Group reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 103 Bicycle Therapeutics shares in Q1 2026, an estimated $1K.
  • Daiwa Securities Group first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 17 quarters.
  • Daiwa Securities Group's Bicycle Therapeutics position peaked at $4K in Q4 2021.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.